The clinical efficacy of FOLFIRI and bevacizumab in combination as first-line therapy of metastatic colorectal cancer

Clin Colorectal Cancer. 2007 Sep;6(9):621-4. doi: 10.1016/S1533-0028(11)70301-2.
No abstract available

Publication types

  • Review

MeSH terms

  • Age Factors
  • Aged
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bevacizumab
  • Camptothecin / analogs & derivatives
  • Camptothecin / therapeutic use
  • Colonic Neoplasms / drug therapy*
  • Colonic Neoplasms / pathology
  • Fluorouracil / therapeutic use
  • Humans
  • Leucovorin / therapeutic use
  • Middle Aged
  • Neoplasm Metastasis
  • Treatment Outcome
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Vascular Endothelial Growth Factor A
  • Bevacizumab
  • Leucovorin
  • Fluorouracil
  • Camptothecin

Supplementary concepts

  • IFL protocol